---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-299290"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2026-07-09T13:31:32+00:00"
generated_at: "2026-07-09T13:32:05.772398+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics appoints former NASA astronaut Kathleen Rubins to board; director Matt Link resigns

## Summary
- Matt Link resigned from the board effective July 2, 2026.
- Kathleen Rubins appointed as Class III director effective July 8, 2026, term until 2029 annual meeting.
- Rubins also appointed to Audit, Compensation, and Governance Committees.
- Rubins is a retired NASA astronaut, microbiologist, and founding director of Trivedi Institute at University of Pittsburgh.
- She previously served on FibroBiologics' Scientific Advisory Board since 2022.

## SEC filing metadata
- accession: 0001193125-26-299290
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2026-07-09T13:31:32+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/0001193125-26-299290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/fblg-20260702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-299290
- JSON: https://secwatch.observer/filing/0001193125-26-299290.json
- Plain text: https://secwatch.observer/filing/0001193125-26-299290.txt

## Key facts
- Executive change
  Matt Link resigned as Director at FibroBiologics, Inc..
  - Action: resigned
  - Role: Director
  source text: On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/0001193125-26-299290-index.htm
- Executive change
  Kathleen Rubins was appointed as Class III Director at FibroBiologics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312526299290/0001193125-26-299290-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.